PRO

PRO: Mind Medicine Earnings Report Breakdown

May 25 • 1 min read

Psychedelic Invest’s very own Adam Tubero digs into Mind Medicine’s ($MNMD) LSD program, Ibogaine, and the company’s Q1 2022 earnings report. Adam explains why his sentiment around MNMD has started to shift lately. Are you bullish or bearish? Leave your comments over on the Psychedelic Invest YouTube channel.

PRO: atai Life Sciences Q1 2022 Earnings Report Breakdown

May 20 • 1 min read

This week, atai Life Sciences (ATAI), the largest pureplay clinical-stage psychedelic company in our index, just reported financial results for the first quarter of 2022 and provided a business update. What’s the latest news in atai’s drug pipeline? And how much cash did the company burn this quarter compared to the last? Tune in to our…

PRO: Rapid Reactions To Compass Pathways’ Earning Report

May 12 • 1 min read

Compass Pathways ($CMPS) is easily considered to be one of the leaders in the psychedelic sector. Earlier this week, they released their Q1 2022 earnings report. Because Compass has a great deal of funding, they continue to have a massive amount of opportunities in front of them. In the video below, we dig beyond solely…

PRO: A Deeper Dive Into GH Research

May 11 • 1 min read

In our latest PRO episode, Adam Tubero digs into GH Research ($GHRS).

PRO: Last Week in Review – Field Trip, Oregon, Psilocybin, and More

May 2 • 1 min read

In our latest episode, Adam Tubero digs into last week’s Field Trip news, Oregon’ legalization of psilocybin, and a breakdown of natural versus synthetic psilocybin.

Pages: 12345